The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia - Lange, Thoralf; Müller, Martin Christian (Haematologica, the hematology journal, 2013)